Eklund J, Nevanlinna H R
J Med Genet. 1973 Mar;10(1):1-7. doi: 10.1136/jmg.10.1.1.
A nation-wide Rh prevention programme was started in Finland in 1969. Before that, a control series of approximately 1000 Rh-negative mothers giving birth to an Rh-positive child was collected to estimate the number of mothers with antibodies at either three, six, or nine months post partum. During the three-and-a-half year period altogether 14,980 Rh-negative patients were given 250 μg of anti-D immunoglobulin prepared from Finnish raw material in the Central Laboratory of the Dutch Red Cross. Out of those treated before the end of June 1972, 12,720 (97%) were tested four to six months post partum. Seventeen or 0·13% had detectable antibodies; in five of them the infant was ABO incompatible. The number of protected mothers with a subsequent Rh-positive infant was 1017; 10 had formed antibodies before the delivery of the second child. The risk of primary immunization initiated during a single pregnancy was estimated to be 0·35%. In addition, there was approximately a 0·60% risk of forming antibodies by the next Rh-positive pregnancy. The effect of prevention on the prevalence of haemolytic disease was calculated and compared with observed figures.
1969年,芬兰启动了一项全国性的Rh预防计划。在此之前,收集了一组约1000名Rh阴性母亲产下Rh阳性婴儿的对照样本,以估计产后三个月、六个月或九个月时产生抗体的母亲数量。在三年半的时间里,共有14980名Rh阴性患者在荷兰红十字会中央实验室接受了由芬兰原料制备的250μg抗-D免疫球蛋白治疗。在1972年6月底前接受治疗的患者中,12720名(97%)在产后四至六个月接受了检测。其中17名(0.13%)检测到抗体;其中5名婴儿与母亲ABO血型不合。后续产下Rh阳性婴儿的受保护母亲有1017名;其中10名在第二个孩子出生前就已产生抗体。单次妊娠期间初次免疫的风险估计为0.35%。此外,下一次怀有Rh阳性胎儿时产生抗体的风险约为0.60%。计算了预防措施对溶血病患病率的影响,并与观察数据进行了比较。